Slots: One slot has been given out of two total.
Starting in 2024, ADA will accept up to two (2) nominations per institution with one (1) nomination spanning basic through preclinical research and one (1) nomination spanning clinical through public health research.
Each nomination can be for either of the Pathway Program Award types: Initiator or Accelerator. Please be aware that if an institution nominates two (2) applicants with proposed projects covering the same phase of research (i.e. basic through preclinical research studies), one of the submitted applications will be administratively disqualified from consideration for funding.
Deadlines
Internal Deadline: Friday, May 17th, 2024, 5pm PT Closed.
LOI: N/A
External Deadline: Wednesday, July 17th, 2024
Award Information
Award Type: Grant
Anticipated Award Amount: $325,000/year
Who May Serve as Applicant: Awards are available to early-career diabetes investigators proposing innovative and ambitious diabetes-related research programs. Applicants must hold faculty positions and have demonstrated independent productivity in diabetes research. Applicants may currently hold independent NIH funding (K, U or R awards, including an initial R01/U01) but must not have applied for (regardless of outcome), or received, an R01/U01 renewal or a second R01/U01 award. Candidates must be identified through institutional nomination; applications will be accepted only from individuals with the appropriate institution support.
Candidates for Accelerator awards should be in the process of establishing successful, independent diabetes research programs, and have records of independent productivity in research. For this award, demonstration of independent productivity should include that the candidate is currently in an independent faculty position, has demonstrated the ability to perform a particular set of experiments at a high-quality level, including senior author publications (independent of training mentors) and/or has demonstrated the ability to obtain independent funding/support for their work.
If funded, the Principal Investigator must agree to devote at least 75% of their total time and overall effort towards research. This percentage includes time dedicated to the Association-funded grant in addition to grants supported by other funding agencies. Please note that during the award’s duration, the Principal Investigator must commit between 25-50% effort towards the Association funded project. For Accelerator awards, applicants may request up to five (5) years of funding support. The proposed project budget should not exceed $325,000 USD per year (including 30% indirect costs) for a maximum total budget up to $1,625,000 USD over five (5) years.
Link to Award: https://professional.diabetes.org/research-grants/current-funding-opportunities-pathway-stop-diabetes
Process for Limited Submissions
PIs must submit their application as a Limited Submission through the Research Initiatives and Infrastructure (RII) Application Portal: https://rii.usc.edu/oor-portal/. Use the template provided here: RII Limited Submission Applicant Template
Materials to submit include:
- (1) Two-Page Proposal Summary (1” margins; single-spaced; standard font type, e.g. Arial, Helvetica, Times New Roman, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 2-page limit will be excluded from review. You must use the template linked above.
- (2) CV – (5 pages maximum)
Note: The portal requires information about the PIs in addition to department and contact information, including the 10-digit USC ID#, Gender, and Ethnicity. Please have this material prepared before beginning this application.
Purpose
The Pathway to Stop Diabetes® Accelerator award is intended to provide flexible, long-term salary and research support to early career researchers who are proposing innovative and ambitious diabetes-related research programs, and who have distinguished themselves as exceptionally talented and promising research investigators.
These awards are highly competitive and intended to support particularly innovative and transformational ideas that have the potential to have an exceptional impact in diabetes with an emphasis on the investigator’s potential to significantly transform diabetes through research (‘moving the needle’) to improve the lives of people with diabetes.
Visit our Institutionally Limited Submission webpage for more updates and other announcements.